Serentis Acquires Atopic Dermatitis Company Surface Therapeutics
10/2/2007 8:54:33 AM
CAMBRIDGE, UK--(Marketwire - October 02, 2007) - Serentis, a UK-based biopharmaceutical company innovating, acquiring and developing dermatological and wound care products, announced today that it has completed the acquisition of Surface Therapeutics Ltd. ("Surface"). Surface has pioneered research into discovering novel, patented treatments for dermatological diseases.
comments powered by